Neurotrophins as Potential Biomarkers for Pediatric Acute Lymphoblastic Leukemia

Strategic Insights -

Recent research in Porto Alegre, Brazil, has shed light on the role of neurotrophins in Acute Lymphoblastic Leukemia (ALL) in children. Investigators at the Children's Cancer Institute have found that neurotrophins, essential growth factors in cellular development, exhibit significant alterations in the tumor microenvironment of pediatric ALL. These findings suggest that neurotrophins may serve as potential biomarkers for active disease and poor outcome in pediatric ALL. Further studies are necessary to elucidate their precise role and prognostic potential.

Key Takeaways:

  • The study analyzed pediatric ALL samples from a Southern Brazil cohort, collected between 2011 and 2021.
  • Neurotrophin levels were quantified via ELISA, and survival analysis was performed using Kaplan-Meier curves.
  • Gene expression data were sourced from public genomic repositories and analyzed with R software version 4.0.5.
  • Pro-BDNF, BDNF, and NGF levels were significantly lower at diagnosis in pediatric ALL patients compared to healthy controls.
  • Reduced pro-BDNF levels were associated with unfavorable outcomes.
  • NGF and sortilin were highly expressed in healthy samples, while BDNF and p75 were predominant in T-ALL and B-ALL, respectively.
  • Neurotrophins show significant alterations in the tumor microenvironment of pediatric ALL.

The research involved collaboration between the Children's Cancer Institute and the National Institute of Science and Technology in Childhood Cancer Biology and Pediatric Oncology.

Statistics:

  • 2011-2021: The period during which pediatric ALL samples were collected from a Southern Brazil cohort.
  • 150: The number of pediatric ALL samples analyzed in the study.
  • 17.10.1623: The article reference number for the research study.
  • 202.5: The version of R software used for analyzing gene expression data.

Sources:

  • "Neurotrophins as Potential Biomarkers for Active Disease and Poor Outcome in Pediatric Acute Lymphoblastic Leukemia." Cancers, 2025;17(10):1623.
  • Children's Cancer Institute, Porto Alegre, Brazil.
  • National Institute of Science and Technology in Childhood Cancer Biology and Pediatric Oncology.
  • Mdpi, St Alban-Anlage 66, Ch-4052 Basel, Switzerland.
  • The abstract can be accessed at: https://pubmed.ncbi.nlm.nih.gov/15876123